CHOLEDYL EXPECTORANT 50 MG / 5 ML
GUAIFENESIN : 50 MG / 5 ML OXTRIPHYLLINE : 100 MG / 5 ML · DIN 00476374 · SEARCHLIGHT PHARMA INC
Health Canada status: MARKETED
What is CHOLEDYL EXPECTORANT?
CHOLEDYL EXPECTORANT 50 MG / 5 ML contains GUAIFENESIN : 50 MG / 5 ML OXTRIPHYLLINE : 100 MG / 5 ML. It is listed in the Health Canada Drug Product Database under DIN 00476374, held by SEARCHLIGHT PHARMA INC, supplied as SOLUTION for ORAL administration. Health Canada currently lists it as marketed, status dated 20-Oct-2022. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is CHOLEDYL EXPECTORANT used for?
Symptomatic relief of reversible bronchoconstriction associated with bronchial asthma, chronic obstructive pulmonary emphysema, chronic bronchitis, and where expectoration is required.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 00476374 |
|---|---|
| Brand name | CHOLEDYL EXPECTORANT |
| Generic / active ingredient | GUAIFENESIN : 50 MG / 5 ML OXTRIPHYLLINE : 100 MG / 5 ML |
| Manufacturer | SEARCHLIGHT PHARMA INC |
| Strength | 50 MG / 5 ML |
| Dosage form | SOLUTION |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | R03DA54 THEOPHYLLINE, COMBINATIONS EXCL. PSYCHOLEPTICS |
| AHFS class | 48:16.00 ; 86:16.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 20-Oct-2022 |
| Original market date | 1981-12-31 00:00:00 |
How is it administered?
Patients over 14 years: 10 mL 4 times daily; 10 to 14 years: 5 mL 4 times daily. Not recommended for children under 10 years of age.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store at controlled room temperature 15 to 25°C.
How is it supplied?
Bottles of 250 mL and 500 mL.
Contraindications
Hypersensitivity to theophylline derivatives; coronary artery disease where myocardial stimulation is harmful; underlying seizure disorders; peptic ulcer.
Warnings and precautions
Small margin of safety in children. Serious toxicity (arrhythmias, convulsions, death) may occur without warning. Reduced clearance in elderly, hepatic/cardiac failure, or viral infections.
What can be used instead?
Other Canadian products sharing ATC code R03DA54 THEOPHYLLINE, COMBINATIONS EXCL. PSYCHOLEPTICS. 1 of 12 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| BRONCHYL SYR | 500 MG / 10 ML | LIQUID | CARMARAN LTÉE | CANCELLED POST MARKET | DIN 00545090 |
| I D M EXPECTORANT TAB | 12 MG | TABLET | ROUGIER PHARMA DIVISION OF RATIOPHARM INC | CANCELLED POST MARKET | DIN 00334510 |
| IDM TAB | 140 MG | TABLET | ROUGIER PHARMA DIVISION OF RATIOPHARM INC | CANCELLED POST MARKET | DIN 00356123 |
| PMS-OXTRIPHYLLINE ELIXIR | 20 MG | ELIXIR | PHARMASCIENCE INC | CANCELLED POST MARKET | DIN 00792942 |
| PULMO SEPTOL SIROP | .06 MG | SYRUP | LES LABORATOIRES BIO-SANTÉ INC. | CANCELLED POST MARKET | DIN 00721301 |
| RATIO-THEO-BRONC | 16 MG | SYRUP | RATIOPHARM INC DIVISION OF TEVA CANADA LIMITED | CANCELLED POST MARKET | DIN 00317225 |
| THEOPHYLLINE 0.8MG AND 5% DEXTROSE INJ | .8 MG | SOLUTION | BAXTER CORPORATION | CANCELLED POST MARKET | DIN 00828718 |
| THEOPHYLLINE 0.8MG/ML IN 5% DEXTROSE INJ | 5.0 % | SOLUTION | HOSPIRA HEALTHCARE ULC | CANCELLED POST MARKET | DIN 00640093 |
| THEOPHYLLINE 1.6MG AND 5% DEXTROSE INJ | 50 MG | SOLUTION | BAXTER CORPORATION | CANCELLED POST MARKET | DIN 00828726 |
| THEOPHYLLINE 4MG AND 5% DEXTROSE INJ | 4 MG | SOLUTION | BAXTER CORPORATION | CANCELLED POST MARKET | DIN 00828742 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.